10 Questions
What is the primary cause of most cases of Acute Myeloid Leukemia (AML)?
Acquired genetic mutations, including chromosomal translocations, inversions, and deletions.
What is the most significant risk factor for developing AML, and how does it impact incidence?
Age, with incidence increasing with age, and a median age at diagnosis around 70 years.
What are the primary symptoms of anemia in AML patients?
Fatigue, weakness, and shortness of breath.
What is the primary purpose of a bone marrow biopsy in AML diagnosis?
To examine bone marrow cells for blasts, morphology, and cytogenetics.
What is the significance of cytogenetic analysis in AML diagnosis?
It helps identify chromosomal abnormalities and genetic mutations.
What is the primary purpose of molecular testing in AML diagnosis?
To identify specific genetic mutations, such as FLT3 and NPM1.
What is the overall 5-year survival rate for adults with AML?
Around 25-30%.
What is the primary purpose of risk stratification in AML prognosis?
To classify patients into low, intermediate, or high risk based on cytogenetic and molecular features.
What is the primary purpose of induction chemotherapy in AML treatment?
To achieve remission.
What is the primary purpose of targeted therapy in AML treatment?
To inhibit specific molecular pathways, such as FLT3 and IDH1/2.
Study Notes
Acute Myeloid Leukemia (AML)
Etiology
- Genetic mutations: Most cases of AML result from acquired genetic mutations, including chromosomal translocations, inversions, and deletions.
- Risk factors: Exposure to radiation, benzene, and certain chemicals; previous chemotherapy or radiation therapy; genetic disorders such as Down syndrome; and certain blood disorders.
- Age: Incidence increases with age, with median age at diagnosis around 70 years.
Symptoms
- Anemia: Fatigue, weakness, shortness of breath
- Infections: Fever, recurrent infections, or delayed healing
- Easy bleeding: Petechiae, bruising, or prolonged bleeding
- Bone pain: Pain or tenderness in bones, joints, or soft tissues
- Weight loss: Unexplained weight loss or loss of appetite
- Lymphadenopathy: Enlarged lymph nodes
Diagnosis
- Complete Blood Count (CBC): Evaluate for anemia, thrombocytopenia, and leukocytosis
- Bone Marrow Biopsy: Examine bone marrow cells for blasts, morphology, and cytogenetics
- Cytogenetic Analysis: Identify chromosomal abnormalities and genetic mutations
- Immunophenotyping: Determine the lineage of leukemia cells (myeloid, lymphoid, or mixed)
- Molecular Testing: Identify specific genetic mutations (e.g., FLT3, NPM1)
Prognosis
- Overall survival rate: 5-year survival rate around 25-30% for adults, higher for children and younger adults
- Risk stratification: Based on cytogenetic and molecular features, patients are classified into low, intermediate, or high risk
- Prognostic factors: Age, performance status, white blood cell count, and presence of certain mutations affect prognosis
Treatment Options
- Induction chemotherapy: Combination of cytotoxic agents to achieve remission
- Consolidation therapy: Post-remission therapy to prevent relapse
- Stem cell transplantation: Autologous or allogenic transplantation for high-risk patients
- Targeted therapy: Inhibitors of specific molecular pathways (e.g., FLT3, IDH1/2)
- Supportive care: Manage symptoms and prevent complications with blood transfusions, antibiotics, and growth factors
Acute Myeloid Leukemia (AML)
Etiology
- Genetic mutations, including chromosomal translocations, inversions, and deletions, are the primary cause of most AML cases
- Exposure to radiation, benzene, and certain chemicals are significant risk factors
- Previous chemotherapy or radiation therapy, genetic disorders like Down syndrome, and certain blood disorders also increase the risk of AML
- The incidence of AML increases with age, with a median age of diagnosis around 70 years
Symptoms
- Anemia leads to fatigue, weakness, and shortness of breath
- Infections cause fever, recurrent infections, or delayed healing
- Easy bleeding is characterized by petechiae, bruising, or prolonged bleeding
- Bone pain is a common symptom, manifesting as pain or tenderness in bones, joints, or soft tissues
- Weight loss may occur due to unexplained weight loss or loss of appetite
- Lymphadenopathy is marked by enlarged lymph nodes
Diagnosis
- Complete Blood Count (CBC) evaluates for anemia, thrombocytopenia, and leukocytosis
- Bone Marrow Biopsy examines bone marrow cells for blasts, morphology, and cytogenetics
- Cytogenetic Analysis identifies chromosomal abnormalities and genetic mutations
- Immunophenotyping determines the lineage of leukemia cells (myeloid, lymphoid, or mixed)
- Molecular Testing identifies specific genetic mutations (e.g., FLT3, NPM1)
Prognosis
- The overall 5-year survival rate for adults is around 25-30%, higher for children and younger adults
- Risk stratification is based on cytogenetic and molecular features, categorizing patients into low, intermediate, or high risk
- Age, performance status, white blood cell count, and presence of certain mutations affect prognosis
Treatment Options
- Induction chemotherapy involves a combination of cytotoxic agents to achieve remission
- Consolidation therapy is post-remission therapy to prevent relapse
- Stem cell transplantation, either autologous or allogenic, is used for high-risk patients
- Targeted therapy involves inhibitors of specific molecular pathways (e.g., FLT3, IDH1/2)
- Supportive care manages symptoms and prevents complications with blood transfusions, antibiotics, and growth factors
Test your knowledge of Acute Myeloid Leukemia (AML), including its etiology, risk factors, symptoms, and more.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
